195 related articles for article (PubMed ID: 22534474)
1. Assessment of BRAF and KIT mutations in Japanese melanoma patients.
Ashida A; Uhara H; Kiniwa Y; Oguchi M; Murata H; Goto Y; Uchiyama A; Ogawa E; Hayashi K; Koga H; Okuyama R
J Dermatol Sci; 2012 Jun; 66(3):240-2. PubMed ID: 22534474
[No Abstract] [Full Text] [Related]
2. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
3. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
4. KIT gene mutations and copy number in melanoma subtypes.
Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
6. KIT, NRAS, and BRAF mutations in nail apparatus melanoma.
Dika E; Altimari A; Patrizi A; Gruppioni E; Fiorentino M; Piraccini BM; Misciali C; Barisani A; Fanti PA
Pigment Cell Melanoma Res; 2013 Sep; 26(5):758-60. PubMed ID: 23782496
[No Abstract] [Full Text] [Related]
7. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
[TBL] [Abstract][Full Text] [Related]
8. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
9. The molecular profile of metastatic melanoma in Australia.
Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
[TBL] [Abstract][Full Text] [Related]
10. B-RAF and melanocytic neoplasia.
Gill M; Celebi JT
J Am Acad Dermatol; 2005 Jul; 53(1):108-14. PubMed ID: 15965430
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population.
Gutiérrez-Castañeda LD; Gamboa M; Nova JA; Pulido L; Tovar-Parra JD
Biomed Res Int; 2020; 2020():2046947. PubMed ID: 32775409
[TBL] [Abstract][Full Text] [Related]
12. MC1R germline variants confer risk for BRAF-mutant melanoma.
Landi MT; Bauer J; Pfeiffer RM; Elder DE; Hulley B; Minghetti P; Calista D; Kanetsky PA; Pinkel D; Bastian BC
Science; 2006 Jul; 313(5786):521-2. PubMed ID: 16809487
[TBL] [Abstract][Full Text] [Related]
13. Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.
Sondak VK; Smalley K
Pigment Cell Melanoma Res; 2009 Aug; 22(4):386-7. PubMed ID: 19624312
[No Abstract] [Full Text] [Related]
14. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
15. BRAF and c-kit gene copy number in mutation-positive malignant melanoma.
Willmore-Payne C; Holden JA; Hirschowitz S; Layfield LJ
Hum Pathol; 2006 May; 37(5):520-7. PubMed ID: 16647948
[TBL] [Abstract][Full Text] [Related]
16. Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1.
Skorokhod A; Capper D; von Deimling A; Enk A; Helmbold P
J Am Acad Dermatol; 2012 Sep; 67(3):488-91. PubMed ID: 22890732
[No Abstract] [Full Text] [Related]
17. Clinicopathological and molecular study of penile melanoma.
Oxley JD; Corbishley C; Down L; Watkin N; Dickerson D; Wong NA
J Clin Pathol; 2012 Mar; 65(3):228-31. PubMed ID: 22011445
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
[TBL] [Abstract][Full Text] [Related]
19. Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity.
Fusi A; Berdel R; Havemann S; Nonnenmacher A; Keilholz U
Eur J Cancer; 2011 Sep; 47(13):1971-6. PubMed ID: 21570823
[TBL] [Abstract][Full Text] [Related]
20. Molecular biology of melanoma.
Swick JM; Maize JC
J Am Acad Dermatol; 2012 Nov; 67(5):1049-54. PubMed ID: 22459362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]